Indefinite Delivery Contract 75D30124D18414
Award Date
1/2/24
Last Date to Order
2/28/25
Federal Agency
CDC Pittsburgh
Awardee
Seqirus USA Inc.
Ultimate Awardee
Not listed
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Pricing Type
Firm Fixed Price
Legislative Mandate
Not listed
National Interest Action
None
Award Type
Multiple
Primary Consortia Member
Not listed
Similar IDVs
This Indefinite Delivery Contract (IDC) was awarded by the Centers for Disease Control and Prevention (CDC) to Seqirus USA Inc., a global biotechnology company specializing in influenza vaccine development, manufacturing, and delivery. The $410,587,500 multiple-award IDC covers the procurement of 2025-2026 pediatric flu vaccines for the federal government. As a registered federal contractor since 2008, Seqirus USA Inc. has extensive experience supplying influenza vaccines to various government...
This Indefinite Delivery Contract (IDC) was awarded by the Centers for Disease Control and Prevention (CDC) to Seqirus USA Inc. to provide pediatric and adult influenza vaccines for the 2022-2023 season. The contract has a total ceiling value of $381,759,818.50 and covers the period from January 3, 2019 to February 28, 2019. Seqirus USA Inc., a global biotechnology company specializing in influenza vaccine development and delivery, will serve as the prime contractor on this multiple award IDC to...
The Centers for Disease Control and Prevention awarded Seqirus USA Inc. a multiple award indefinite delivery contract with a potential value of $129.8 million to supply pediatric influenza vaccines through February 2028. Task orders will be issued against the contract to procure required vaccines annually to support the CDC's national immunization programs. As a leading manufacturer of influenza vaccines, Seqirus will deliver various formulations of pediatric flu vaccines to the CDC for...
The Centers for Disease Control and Prevention (CDC) has awarded an Indefinite Delivery Contract (IDC) to Seqirus USA Inc., through its Seqirus USA, Inc. division, for the procurement of pediatric influenza vaccines. The contract has a ceiling value of $208,520,000 and a performance period through February 28, 2023. Under this IDC, Seqirus will provide between 100 doses to 50 million doses of pediatric influenza vaccines, in various presentations and National Drug Codes, to support...
This indefinite delivery contract (IDC) was awarded by the Centers for Disease Control and Prevention (CDC) to Seqirus USA Inc., a global biotechnology company specializing in influenza vaccine development, manufacturing, and delivery. The $253,319,000 multiple-award IDC has a period of performance from December 31, 2024 to February 28, 2026 and is intended to provide adult flu vaccines to support the CDC's annual immunization programs. Seqirus, through its Seqirus USA, Inc. division, is a...
This Indefinite Delivery Contract (IDC) was awarded by the Centers for Disease Control and Prevention (CDC) to Seqirus USA Inc., a global biotechnology company specializing in influenza vaccine development, manufacturing, and delivery. The $143,324,800 contract is for the procurement of adult influenza vaccines for the 2022-2023 flu season, with a period of performance from the award date of December 31, 2021 through February 28, 2023. The contract does not utilize any set-asides and was awarded...
This Indefinite Delivery Contract (IDC) was awarded by the Centers for Disease Control and Prevention (CDC) to Seqirus USA Inc., a global biotechnology company specializing in influenza vaccine development and delivery. The $143 million IDC is for the supply of adult influenza vaccines, and a separate $208 million IDC is for pediatric influenza vaccines, to support the CDC's nationwide immunization programs from 2022-2023. Seqirus USA Inc. has also been awarded several other high-value...
The Centers for Disease Control and Prevention awarded a single award indefinite delivery contract to Seqirus USA Inc. with a potential value of $180,705,000. The contract aims to procure pediatric influenza vaccines for children ages 0 through 18 years old to support immunization programs under Section 317(j) of the Public Health Service Act and the Vaccines for Children program. Task orders will be issued against the contract to purchase required vaccines each flu season through February 28,...
This indefinite delivery contract (IDC) was awarded by the Centers for Disease Control and Prevention (CDC), a civilian agency within the Department of Health and Human Services, to Seqirus USA Inc. The contract has a ceiling value of $27,015,000 and is for the delivery of adult influenza vaccines for the 2019-2020 flu season. Seqirus USA Inc., through its Seqirus USA, Inc. division, is a global biotechnology company specializing in the development, manufacturing, and delivery of influenza...
The federal contract IDV being summarized is a multiple award Indefinite Delivery Contract (IDC) awarded by the Centers for Disease Control and Prevention (CDC) to Seqirus USA Inc. for the delivery of adult influenza vaccines for the 2024-2025 flu season. The $215,741,000 IDC covers a range of influenza vaccine products and presentations, including multi-dose vials, pre-filled syringes, and specialized formulations for different age groups. Seqirus, a foreign-owned for-profit manufacturer,...